Novel drug preventing protein recycling shows potential for treating leukemia

Apr 19, 2007

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found that a novel targeted therapy effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins.

In the March online issue of the journal Blood, investigators reported that the new proteasome inhibitor, NPI-0052, not only successfully kills leukemia cells, but also shows greater efficacy than its predecessor bortezomib when combined with other agents in animal models.

According to researchers, proteasomes clean out mutated or damaged proteins within cells, which promotes cell growth and allows cancer cells to rapidly reproduce. Proteasome inhibitors block this process, resulting in apoptosis, or cell death, of the malignant cells.

Bortezomib is the first and only FDA-approved proteasome inhibitor. Although it is effective for treating multiple myeloma and mantle cell lymphoma, it was proven to be ineffective as a single agent against leukemia in clinical trials. NPI-0052 varies from bortezomib in ways that researchers at M. D. Anderson hope will make NPI-0052 effective in a human clinical trial.

"NPI-0052 targets the proteasome through different intermediaries and is more potent than bortezomib in leukemia cells," says senior author Joya Chandra, Ph.D., assistant professor of pediatrics from the Children's Cancer Hospital at M. D. Anderson. "Therefore we can use less of the drug to inhibit the proteasome."

NPI-0052 inhibits the main enzymatic activity of the proteasome three times more effectively than bortezomib as a single agent. When combined with a histone deacetylase (HDAC) inhibitor, another anti-cancer agent, NPI-0052 achieves four-fold greater synergistic effects than bortezomib.

M. D. Anderson currently has a Phase I clinical trial led by principal investigator Razelle Kurzrock, M.D., to test NPI-0052 on adult patients with solid tumor malignancies and recurrent lymphoma. Chandra's group is the first group to be studying the effects of the drug in acute leukemia models.

"This drug, so far, has shown efficacy in animal models of leukemia, myeloma and colon cancer, and it has worked to kill multiple myeloma cells resistant to bortezomib," says Chandra. "As a result of our research, we're looking at the feasibility of combining NPI-0052 with HDAC inhibitors in the future to treat leukemia."

Source: University of Texas M. D. Anderson Cancer Center

Explore further: Delayed introduction to gluten appears not to prevent celiac disease in at-risk infants

add to favorites email to friend print save as pdf

Related Stories

Driving cancer cells to suicide

7 hours ago

Ludwig Maximilian University of Munich researchers report that a new class of chemical compounds makes cancer cells more sensitive to chemotherapeutic drugs. They have also pinpointed the relevant target ...

Chemists recruit anthrax to deliver cancer drugs

Sep 25, 2014

Bacillus anthracis bacteria have very efficient machinery for injecting toxic proteins into cells, leading to the potentially deadly infection known as anthrax. A team of MIT researchers has now hijacked ...

New functions for chromatin remodelers

Aug 28, 2014

Large molecular motors consisting of up to a dozen different proteins regulate access to the genome, which is essential for the transcription of genes and for the repair of DNA damage. Susan Gasser and her ...

Tiny diamonds to boost treatment of chemoresistant leukemia

Sep 11, 2013

By binding multiple molecules of a common leukemia drug with nanodiamonds, scientists from the National University of Singapore (NUS) and University of California, Los Angeles (UCLA) managed to boost the delivery of the drug ...

'Nanodaisies' deliver drug cocktail to cancer cells

May 28, 2014

(Phys.org) —Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anti-cancer drugs and are capable of introducing a "cocktail" of multiple ...

Recommended for you

Ebola death toll passes 3,300: WHO

1 hour ago

The death toll in the world's worst-ever Ebola epidemic has now soared past 3,300, with the virus killing almost half of the more than 7,000 people it has infected, according to World Health Organization figures released ...

Dallas ER sent Ebola-infected patient home

1 hour ago

A Dallas emergency room sent a man with Ebola home last week, even though he told a nurse that he had been in disease-ravaged West Africa, and officials at the hospital are considering if they would have ...

User comments : 0